Neuralink Receives FDA Approval , For In-Human Clinical Trials.<br />On May 25, Elon Musk's neurotech startup Neuralink <br />received Food and Drug Administration approval <br />to conduct its first clinical study on humans.<br />On May 25, Elon Musk's neurotech startup Neuralink <br />received Food and Drug Administration approval <br />to conduct its first clinical study on humans.<br />NBC reports that Neuralink, <br />which was co-founded by Musk, <br />is developing a brain implant called the Link.<br />The implant, which operated solely on <br />neural signals, aims to help patients with <br />severe paralysis control external technologies.<br />The implant, which operated solely on <br />neural signals, aims to help patients with <br />severe paralysis control external technologies.<br />This is the result of incredible work by <br />the Neuralink team in close collaboration <br />with the FDA and represents an important <br />first step that will one day allow our <br />technology to help many people, Neuralink, via Twitter.<br />This is the result of incredible work by <br />the Neuralink team in close collaboration <br />with the FDA and represents an important <br />first step that will one day allow our <br />technology to help many people, Neuralink, via Twitter.<br />NBC reports that the extent of <br />the approval trial remains unknown. .<br />On Twitter, Neuralink said that <br />patient recruitment is not open <br />yet for the upcoming clinical trial.<br />Neuralink requires patients to undergo an invasive <br />brain surgery to install the Link, a minuscule <br />implant connected to a series of neural threads. .<br />Neuralink requires patients to undergo an invasive <br />brain surgery to install the Link, a minuscule <br />implant connected to a series of neural threads. .<br />NBC reports that the FDA's approval for <br />in-human study represents a major win for <br />Neuralink, which has faced a number of setbacks. .<br />In March, Reuters reports that the FDA rejected <br />the company's application for human trials, citing <br />"dozens" of issues that needed to be addressed.
